Moreover, it renders the possibility of a novel therapeutic target on the signaling of Netrin-1/DCC/GluA1, which could provide substantial benefit to patients with IBS induced by EALs in clinics. The gene discussed is GRIA1; the disease is irritable bowel syndrome.